Literature DB >> 9824154

Interaction with cyclin-dependent kinases and PCNA modulates proteasome-dependent degradation of p21.

C Cayrol1, B Ducommun.   

Abstract

The cyclin-dependent kinase (CDK) inhibitor p21(Cip1/Waf1) plays an essential role in the control of cell proliferation by modulating the activity of cyclin/CDK complexes in response to various intracellular or extracellular signals. Small variations in p21 expression levels may determine whether it acts as an inhibitor or an assembly factor for cyclin/CDK complexes. It is therefore critical to better characterize the mechanisms regulating p21 abundance. Here, we show, using a tetracycline-regulated system in p53-deficient DLD-1 human colon cancer cells, that p21 protein levels and stability are regulated by the proteasome-dependent degradation pathway and by association with its partners, CDKs and PCNA. A p21 mutant deficient for interaction with CDKs, p21CDK-, displayed an enhanced stability and greatly reduced sensitivity to proteasome-mediated proteolysis, indicating that association with cyclin/CDK complexes may trigger p21 degradation. In contrast, a p21 mutant impaired in the interaction with PCNA, p21PCNA-, exhibited a decreased stability, suggesting that association with PCNA protects p21 from proteasome-dependent degradation. Furthermore, the abundance of p21 itself, in addition to protein-protein interactions, may also modulate p21 stability since we found that high levels of p21 expression overcome proteasome-dependent regulation of p21 accumulation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9824154     DOI: 10.1038/sj.onc.1202189

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  31 in total

1.  A degradation signal located in the C-terminus of p21WAF1/CIP1 is a binding site for the C8 alpha-subunit of the 20S proteasome.

Authors:  R Touitou; J Richardson; S Bose; M Nakanishi; J Rivett; M J Allday
Journal:  EMBO J       Date:  2001-05-15       Impact factor: 11.598

2.  Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide.

Authors:  Y Gao; S Lecker; M J Post; A J Hietaranta; J Li; R Volk; M Li; K Sato; A K Saluja; M L Steer; A L Goldberg; M Simons
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

3.  APC/C(Cdc20) controls the ubiquitin-mediated degradation of p21 in prometaphase.

Authors:  Virginia Amador; Sheng Ge; Patricia G Santamaría; Daniele Guardavaccaro; Michele Pagano
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

4.  Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase.

Authors:  Fabio P S Santos; Hagop Kantarjian; David McConkey; Susan O'Brien; Stefan Faderl; Gautam Borthakur; Alessandra Ferrajoli; John Wright; Jorge Cortes
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2011-08

5.  DDB2 association with PCNA is required for its degradation after UV-induced DNA damage.

Authors:  Ornella Cazzalini; Paola Perucca; Roberto Mocchi; Sabrina Sommatis; Ennio Prosperi; Lucia Anna Stivala
Journal:  Cell Cycle       Date:  2013-11-04       Impact factor: 4.534

6.  PDK1-dependent activation of atypical PKC leads to degradation of the p21 tumour modifier protein.

Authors:  Mary T Scott; Angela Ingram; Kathryn L Ball
Journal:  EMBO J       Date:  2002-12-16       Impact factor: 11.598

Review 7.  Exploiting replicative stress to treat cancer.

Authors:  Matthias Dobbelstein; Claus Storgaard Sørensen
Journal:  Nat Rev Drug Discov       Date:  2015-05-08       Impact factor: 84.694

8.  Human GTSE-1 regulates p21(CIP1/WAF1) stability conferring resistance to paclitaxel treatment.

Authors:  Débora Rosa Bublik; Massimiliano Scolz; Gianluca Triolo; Martín Monte; Claudio Schneider
Journal:  J Biol Chem       Date:  2009-12-14       Impact factor: 5.157

Review 9.  Bortezomib: a review of its use in patients with multiple myeloma.

Authors:  Monique P Curran; Kate McKeage
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Natural variants of hepatitis B virus X protein have differential effects on the expression of cyclin-dependent kinase inhibitor p21 gene.

Authors:  Hyun Jin Kwun; Kyung Lib Jang
Journal:  Nucleic Acids Res       Date:  2004-04-23       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.